About: Histo-blood group glycans in the context of personalized medicine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Histo-blood group glycans in the context of personalized medicine Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Histo-blood group glycans in the context of personalized medicine
Creator	Dotz, V Wuhrer, M
Source	ArXiv; Elsevier; Medline; PMC
abstract	Abstract Background A subset of histo-blood group antigens including ABO and Lewis are oligosaccharide structures which may be conjugated to lipids or proteins. They are known to be important recognition motifs not only in the context of blood transfusions, but also in infection and cancer development. Scope of review Current knowledge on the molecular background and the implication of histo-blood group glycans in the prevention and therapy of infectious and non-communicable diseases, such as cancer and cardiovascular disease, is presented. Major conclusions Glycan-based histo-blood groups are associated with intestinal microbiota composition, the risk of various diseases as well as therapeutic success of, e.g., vaccination. Their potential as prebiotic or anti-microbial agents, as disease biomarkers and vaccine targets should be further investigated in future studies. For this, recent and future technological advancements will be of particular importance, especially with regard to the unambiguous structural characterization of the glycan portion in combination with information on the protein and lipid carriers of histo-blood group-active glycans in large cohorts. General significance Histo-blood group glycans have a unique linking position in the complex network of genes, oncodevelopmental biological processes, and disease mechanisms. Thus, they are highly promising targets for novel approaches in the field of personalized medicine. This article is part of a Special Issue entitled %22Glycans in personalised medicine%22 Guest Editor: Professor Gordan Lauc.
has issue date	2016-08-31(xsd:dateTime)
bibo:doi	10.1016/j.bbagen.2015.12.026
bibo:pmid	26748235
has license	els-covid
sha1sum (hex)	9ce1aba2a359d35913dd096c55713ee0de990ba5
schema:url	https://doi.org/10.1016/j.bbagen.2015.12.026
resource representing a document's title	Histo-blood group glycans in the context of personalized medicine
has PubMed Central identifier	PMC7117023
has PubMed identifier	26748235
schema:publication	Biochimica et Biophysica Acta (BBA) - General Subjects
resource representing a document's body	covid:9ce1aba2a359d35913dd096c55713ee0de990ba5#body_text
is schema:about of	covid:arg/9ce1aba2a359d35913dd096c55713ee0de990ba5 named entity 'oligosaccharide' named entity 'Histo' named entity 'histo' named entity 'vaccine targets' named entity 'ABO' named entity 'adhesins' named entity 'gastritis' named entity 'FORS' named entity 'ABH' named entity 'sialyl' named entity 'roughly half' named entity 'ABO' named entity 'glycosyltransferases' named entity 'antigens' named entity 'gene' named entity 'MALDI' named entity 'infection' named entity 'antigens' named entity 'glycosylation' named entity 'antigen' named entity 'vaccine' named entity 'antigen' named entity 'chronic infection' named entity 'genotype' named entity 'non-self' named entity 'histo' named entity 'immune response' named entity 'adhesion' named entity 'tumor stage' named entity 'non-secretors' named entity 'antigen' named entity 'enzyme' named entity 'antibodies' named entity 'antigens' named entity 'ABO' named entity 'personalized medicine' named entity 'sialyltransferases' named entity 'FUT2' named entity 'mucins' named entity 'glycan' named entity 'stratifying' named entity 'expression levels' named entity 'biomarkers' named entity 'antigens' named entity 'virus diseases' named entity 'Intestinal microbiome' named entity 'epithelial surfaces' named entity 'follow-up' named entity 'infection' named entity 'A4GALT' named entity 'glycosyltransferases' named entity 'glycans' named entity 'glycosyltransferases' named entity 'FORS' named entity 'globotriaosylceramide' named entity 'tumor marker' named entity 'US National Academies' named entity 'multivalent' named entity 'immunoglobulin' named entity 'genetic diversity' named entity 'Sialyl' named entity 'staining' named entity 'histo' named entity 'histo' named entity 'non-secretor' named entity 'histo' named entity 'pathogen' named entity 'monoclonal antibodies' named entity 'lipids' named entity 'Glycomic' named entity 'histo' named entity 'immunoglobulin' named entity 'produce antibodies' named entity 'sialylation' named entity 'glycans' named entity 'urinary tract infections' named entity 'pathogen' named entity 'vaccines' named entity 'glycan'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software